WhiteOak Capital Pharma and Healthcare Fund Direct Growth
NAV as on 24-04-2025
₹ 13.33
▲0.7%
1D
Inception Returns
26.4%
/yr
Historical NAV & Returns
Absolute
▲
▼
576 people have invested ₹ 36.8L in WhiteOak Capital Pharma and Healthcare Fund Direct Growth in the last three months
About WhiteOak Capital Pharma and Healthcare Fund Direct Growth
WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 6 February, 2024. The fund is managed by Piyush Baranwal. The fund could potentially beat inflation in the long-run.
Key Parameters
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has ₹304 Cr worth of assets under management (AUM) as on Mar 2025 and is less than category average.
- The fund has an expense ratio 0.6.
Returns
WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 26.42% since inception. Over the last 1 year the fund has given a CAGR return of 32.84%.
Holdings
WhiteOak Capital Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Divi's Laboratories Ltd, Lupin Ltd, Max Healthcare Institute Ltd Ordinary Shares
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 500.00 and for SIP is INR 100.00. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has no lock in period.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Overview
| Expense ratio | 0.55% |
Benchmark | BSE Healthcare TR INR |
| AUM | ₹304 Cr |
| Inception Date | 6 February, 2024 |
| Min Lumpsum/SIP | ₹500/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 73.27% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (24-Apr-25)
Fund Distribution
as on (31-Mar-25)
Small cap
34.7%
Large cap
28.7%
Mid cap
27.2%
Sector Allocation
Health
95.4%
Basic Materials
4%
Financial Services
0.6%
All changes are between Jan'25 and Mar'25
- This fund’s returns stands at 8.92% whereas the fund’s underlying benchmark Nifty 500 returns stands at 7.25% as on Mar'25
- This fund outperformed Nifty 500 by 1.67% in Mar'25
- AUM of the fund stands at 303.6 Cr as of Mar'25
- AUM increased by 32.3 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Laurus Labs Ltd's allocation increased from 2.36% to 3.54%
Krishna Institute of Medical Sciences Ltd's allocation increased from 3.08% to 3.85%
Piramal Pharma Ltd's allocation increased from 2.02% to 2.72%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 8.07 % to 7.39 %
Divi's Laboratories Ltd's allocation decreased from 7.03 % to 6.08 %
Max Healthcare Institute Ltd Ordinary Shares's allocation decreased from 7.41 % to 5.14 %
Mid Cap allocation has gone down from 32.6% to 27.2%
Large Cap allocation has gone down from 29.5% to 28.7%
Small Cap allocation has gone up from 28.6% to 34.7%
Cash allocation has gone down from 7.3% to 7.1%
Top 3 Sectors in March were Health, Basic Materials & Industrial
Mar'25
Health
95%
Basic Materials
4%
Financial Services
Feb'25
Health
96%
Basic Materials
3%
Industrial
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 11.3% | 6.3% | |
 Cipla Ltd | 7.39% | 0% | |
 Divi's Laboratories Ltd | 6.08% | -8.1% | |
 Lupin Ltd | 5.58% | 7.5% | |
 Max Healthcare Institute Ltd Ordinary Shares | 5.14% | -30.8% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 32.84% | - | - | 26.42% |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth | 25.47% | 25.13% | 26.81% | 22.86% |
 SBI Healthcare Opportunities Fund Direct Growth | 25.35% | 24.98% | 26.68% | 18.44% |
 LIC MF Healthcare Fund Direct Growth | 22.27% | 17.85% | 19.59% | 20.34% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Krishna Institute of Medical Sciences Ltd | 6.4% |
Loading...
We are taking more time than usual
Piyush Baranwal
Fund Manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, since 6 February 2024
Top funds managed
Fund House
WhiteOak Capital Asset Management Limited
Total Schemes
Total AUM
₹16.47K Cr
as on 31-Mar-2025
Address
602B, 6th Floor,Indiabulls Finance Centre(IFC),1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City
Phone
+91180030003060
Website
http://mf.whiteoakamc.com
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 26.42% since inception which is more than its category average return of 17.91%
Fund Allocations
This fund has an allocation of 92.88% in Equity, 0% in Debt and 7.12% in Cash related instruments
AUM size ₹304 Cr
This fund has AUM of ₹304 Cr which is less than its category average of ₹ 1821 Cr
Expense Ratio 0.55%
This fund has an expense ratio of 0.55% which is less than its category average expense ratio of 1.44%
More funds from WhiteOak
1Y CAGR
▲ 15.97
1Y CAGR
▲ 16.80
1Y CAGR
▲ 18.52
1Y CAGR
▲ 15.16
1Y CAGR
▲ 16.81
Frequently Asked Questions for WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is ₹13.33 as on 24-Apr-2025.
Existing (Absolute + CAGR) as on 24-Apr-2025.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 0.67% | 0.67% |
6 Month Returns | 3.77% | 3.77% |
1 Year Returns | 32.84% | 32.84% |
3 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.55% as on March 2025
₹304 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(11.3%), Cipla Ltd(7.39%), Divi's Laboratories Ltd(6.08%), Lupin Ltd(5.58%), Max Healthcare Institute Ltd Ordinary Shares(5.14%) as on March 2025
Health(88.6%), Basic Materials(3.73%), Financial Services(0.56%) as on March 2025
The alpha ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 9.93 | - | - |
As on March 2025
The alpha for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated against BSE Healthcare TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 1 | - | - |
As on March 2025
The Beta for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 1.08 | - | - |
As on March 2025
The sharpe ratio for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | 20.31 | - | - |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Piyush Baranwal is the fund manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The Exit load of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is 1%